Page 61 - 南京医科大学学报自然科学版
P. 61

第44卷第3期        韩宜霏,许张娣,吴佳竹,等. XPO1基因突变的慢性淋巴细胞白血病临床特征及预后研究[J].
                  2024年3月                     南京医科大学学报(自然科学版),2024,44(3):342-351                        ·351 ·


                    mator of the tumor mutational burden in chronic lympho⁃  [19] LAPALOMBELLA R,SUN Q X,WILLIAMS K,et al.
                    cytic leukemia[J]. Int J Lab Hematol,2021,43(4):683-  Selective inhibitors of nuclear export show that CRM1/
                    692                                                XPO1 is a target in chronic lymphocytic leukemia[J].
               [17] HERNÁNDEZ J Á,HERNÁNDEZ ⁃ SÁNCHEZ M,RO⁃            Blood,2012,120(23):4621-4634
                    DRÍGUEZ⁃VICENTE A E,et al. A low frequency of loss⁃  [20] XU Z D,PAN B H,MIAO Y,et al. Prognostic value and
                    es in 11q chromosome is associated with better outcome  therapeutic targeting of XPO1 in chronic lymphocytic leu⁃
                    and lower rate of genomic mutations in patients with  kemia[J]. Clin Exp Med,2023,23(6):2651-2662
                    chronic lymphocytic leukemia[J]. PLoS One,2015,10  [21] HING Z A,MANTEL R,BECKWITH K A,et al. Selinex⁃
                    (11):e0143073                                      or is effective in acquired resistance to ibrutinib and syn⁃
               [18] MOIA R,TERZI DI BERGAMO L,TALOTTA D,et al.         ergizes with ibrutinib in chronic lymphocytic leukemia
                    XPO1 mutations identify early⁃stage CLL characterized by  [J]. Blood,2015,125(20):3128-3132
                    shorter time to first treatment and enhanced BCR signalling             [收稿日期] 2023-10-11
                    [J].Br J Haematol,2023,203(3):416-425                                       (本文编辑:戴王娟)







                






               (上接第341页)                                               studies[J]. Molecules,2019,24(14):2645
                    a potential bioactive compound with angiogenic,and anti⁃  [25] YU Y Q,LIU K,WEN Z,et al. Double⁃edged effects and
                    bacterial activity for bone tissue engineering[J]. Col⁃  mechanisms of Zn microenvironments on osteogenic ac⁃
                                                                                    2 +
                    loids Surf B Biointerfaces,2018,167:134-143        tivity of BMSCs:osteogenic differentiation or apoptosis
               [22] VIMALRAJ S,RAJALAKSHMI S,RAJ PREETH D,et al.      [J]. RSC Adv,2020,10(25):14915-14927
                    Mixed⁃ligand copper(Ⅱ)complex of quercetin regulate  [26] CHARLTON N C,MASTYUGIN M,TÖRÖK B,et al.
                    osteogenesis and angiogenesis[J]. Mater Sci Eng C Mater  Structural features of small molecule antioxidants and
                    Biol Appl,2018,83:187-194                          strategic modifications to improve potential bioactivity
               [23] JEONG M J,LIM D S,KIM S O,et al. Effect of rosmarinic  [J]. Molecules,2023,28(3):1057
                    acid on differentiation and mineralization of MC3T3 ⁃ E1  [27] NASSARAWA S S,NAYIK G A,GUPTA S D,et al. Chemi⁃
                    osteoblastic cells on titanium surface[J]. Anim Cells  cal aspects of polyphenol ⁃ protein interactions and their
                    Syst,2021,25(1):46-55                              antibacterial activity[J]. Crit Rev Food Sci Nutr,2023,63
               [24] SWISŁOCKA R,REGULSKA E,KARPI N SKA J,et al.       (28):9482-9505
                    Molecular structure and antioxidant properties of alkali                [收稿日期] 2023-09-07
                    metal salts of rosmarinic acid. experimental and DFT                        (本文编辑:陈汐敏)
   56   57   58   59   60   61   62   63   64   65   66